Jonathan C Trent Selected Research

Angiosarcoma of the breast

7/2021	Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable.
1/2019	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonathan C Trent Research Topics

Disease

56	Neoplasms (Cancer) 05/2022 - 10/2002
38	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 09/2021 - 12/2003
25	Sarcoma (Soft Tissue Sarcoma) 10/2021 - 10/2002
5	Chondrosarcoma 01/2022 - 01/2015
3	Synovial Sarcoma (Synovioma) 05/2022 - 02/2005
3	Aggressive Fibromatosis (Desmoid) 01/2022 - 10/2016
3	Hemangiosarcoma (Angiosarcoma) 09/2021 - 01/2019
3	Osteosarcoma (Osteogenic Sarcoma) 05/2015 - 03/2007
3	Edema (Dropsy) 01/2012 - 01/2010
3	Cardiotoxicity 02/2011 - 07/2003
3	Neoplasm Metastasis (Metastasis) 12/2009 - 02/2005
2	Leiomyosarcoma 01/2022 - 11/2010
2	Disease Progression 09/2021 - 01/2007
2	Angiosarcoma of the breast 07/2021 - 01/2019
2	Leukopenia 01/2021 - 07/2012
2	Fatigue 01/2019 - 02/2011
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2015 - 11/2009
2	Rhabdomyosarcoma 06/2015 - 11/2007
2	Ewing Sarcoma (Sarcoma, Ewing) 05/2015 - 01/2011
2	Solitary Fibrous Tumors 05/2013 - 11/2011
2	Breast Neoplasms (Breast Cancer) 07/2012 - 07/2003
1	Leiomyomatosis 01/2022
1	Wounds and Injuries (Trauma) 10/2021
1	Microsatellite Instability 09/2021
1	Pathologic Complete Response 07/2021
1	COVID-19 01/2021
1	Carcinogenesis 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Ovarian Epithelial Carcinoma 01/2019

Drug/Important Bio-Agent (IBA)

32	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 09/2004
9	Tyrosine Kinase InhibitorsIBA 11/2019 - 01/2005
7	Phosphotransferases (Kinase)IBA 09/2021 - 09/2004
6	EnzymesIBA 01/2020 - 07/2012
5	Sunitinib (Sutent)FDA Link 09/2021 - 04/2010
5	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2020 - 01/2015
5	pazopanib FDA Link 01/2019 - 07/2013
5	Pharmaceutical PreparationsIBA 01/2018 - 11/2009
5	Proteins (Proteins, Gene)FDA Link 11/2011 - 02/2005
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 12/2003
4	Biomarkers (Surrogate Marker)IBA 09/2021 - 05/2007
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 10/2002
3	Immune Checkpoint InhibitorsIBA 11/2019 - 01/2019
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2019 - 02/2008
3	Ifosfamide FDA LinkGeneric 01/2019 - 12/2003
3	Biological ProductsIBA 12/2016 - 07/2003
3	Small Interfering RNA (siRNA)IBA 01/2011 - 03/2007
2	Estrogen ReceptorsIBA 01/2022 - 07/2012
2	Circulating Tumor DNAIBA 11/2020 - 01/2018
2	ivosidenibIBA 01/2020 - 01/2019
2	alpha-hydroxyglutarateIBA 01/2020 - 01/2015
2	Docetaxel (Taxotere)FDA Link 01/2019 - 07/2003
2	pembrolizumabIBA 01/2019 - 01/2019
2	TrabectedinIBA 01/2019 - 12/2012
2	Axitinib (AG 013736)IBA 01/2019 - 01/2019
2	Gemcitabine FDA Link 01/2019 - 01/2019
2	Succinate Dehydrogenase (Fumarate Reductase)IBA 10/2017 - 07/2016
2	Temozolomide (Temodar)FDA LinkGeneric 11/2011 - 12/2003
2	Platelet-Derived Growth FactorIBA 07/2010 - 07/2008
2	Insulin-Like PeptidesIBA 11/2009 - 10/2006
2	Dasatinib (BMS 354825)FDA Link 08/2009 - 03/2007
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2008 - 07/2003
2	tyrosine receptor (receptor, tyrosine)IBA 11/2007 - 02/2005
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2003 - 10/2002
1	RNA Polymerase II (RNA Polymerase B)IBA 05/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2022
1	Cytotoxins (Cytolysins)IBA 05/2022
1	Vinca AlkaloidsIBA 01/2022
1	CrizotinibIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	Biocompatible Materials (Biomaterials)IBA 10/2021
1	Tumor Biomarkers (Tumor Markers)IBA 09/2021
1	Tyrosine (L-Tyrosine)FDA Link 09/2021
1	AlbuminsIBA 01/2021
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2021
1	C-Reactive ProteinIBA 01/2021
1	infigratinibIBA 01/2021
1	ProcalcitoninIBA 01/2021
1	Urea (Carbamide)FDA LinkGeneric 01/2021
1	NitrogenIBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	IntegrinsIBA 01/2020
1	DioxygenasesIBA 01/2020
1	ontuxizumabIBA 01/2019
1	isocitric acid (isocitrate)IBA 01/2019
1	IpilimumabIBA 01/2019
1	NivolumabIBA 01/2019
1	Alkaline PhosphataseIBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Phosphorus (Red Phosphorus)IBA 01/2019

Therapy/Procedure

46	Therapeutics 01/2022 - 07/2003
14	Drug Therapy (Chemotherapy) 01/2022 - 11/2003
7	Radiotherapy 09/2021 - 11/2003
5	Immunotherapy 09/2021 - 07/2012
3	Neoadjuvant Therapy 07/2021 - 03/2010
3	Adjuvant Chemotherapy 01/2019 - 11/2003
2	Precision Medicine 11/2019 - 01/2018
1	Breast Implants (Breast Implant) 10/2021
1	Combined Modality Therapy 07/2021
1	Genomic Medicine 11/2019